NASDAQ : ESLA

Estrella Immunopharma, Inc.

$0.78 USD

$0.02 (2.04%)

Volume
78.74K
Average Volume
41.72K
Market Capitalization
$33.57M
P/E Ratio
-2.25
Dividend Yield
0.00%
Price Target
Year High
$3.15
Year Low
$0.73
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$0.24
Company Overview

NASDAQ

Cheng Liu

Biotechnology

Healthcare

ESLA

3

US

USD

510 318 9098

297584104

0001844417

Liquidity Metrics

0.00

0.24

0.24

0.22

0.00

Sales & Valuation

-$

0.00

-6.23

-4.19

-0.19

Profitability

-$0.35

-$13.06M

0.00%

0.00%

167.91%

-362.33%

P/E Metrics

-2.25

0.11

0.11

Analyst Price Target & Rating

Sell

2/5

1 Analysts

%

Financial Health Scores

-26.96

2/9

-$6.77M

$3.66M

$8.93M

-$13.25M

Key Metrics (TTM)

$31.64M

0.00

-2.39

0.24

167.91%

251.42%

-40.33%

-23.89%

0 days

Company Executives
Name Title
Jiandong Xu Chief Financial Officer
Cheng Liu Chief Executive Officer, President & Director
Poll Results

No votes yet today — be the first to share your view!

About Estrella Immunopharma, Inc. (NASDAQ:ESLA) Stock

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California. ...

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma

2026-07-24 08:00:00

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractor.

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

2026-05-05 08:00:00

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerg.

Frequently Asked Questions

What is the current Estrella Immunopharma, Inc. (ESLA) stock price?

Estrella Immunopharma, Inc.(NASDAQ:ESLA) stock price is $0.78 in the last trading session. During the trading session, ESLA stock reached the peak price of $3.15 while $0.73 was the lowest point it dropped to. The percentage change in ESLA stock occurred in the recent session was 2.04% while the dollar amount for the price change in ESLA stock was $0.02.

ESLA's industry and sector of operation?

The NASDAQ listed ESLA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ESLA?

Jiandong Xu | Chief Financial Officer
Cheng Liu | Chief Executive Officer, President & Director
|
|
|

How many employees does ESLA have?

Number of ESLA employees currently stands at 3. ESLA operates from 5858 Horton Street, EmeryVille, CA 94608, US.

Link for ESLA official website?

Official Website of ESLA is: https://www.estrellabio.com

How do I contact ESLA?

ESLA could be contacted at phone #510 318 9098 and can also be accessed through its website. ESLA operates from 5858 Horton Street, EmeryVille, CA 94608, US.

How many shares of ESLA are traded daily?

The average number of ESLA shares traded daily for last 3 months was 41.72K.

What is the market cap of ESLA currently?

The market value of ESLA currently stands at $33.57M with its latest stock price at $0.78